Sana Biotechnology (SANA) Stock Price & Analysis

SANA$2.02+0.01 +0.50%
BiotechnologyGrowth Stock
Compare
Market cap$605.26MEnterprise value$618.00MRevenue (TTM)$0Market position—

Score

64
Neutral
Value
59
Quality
32
Growth
100

AI Analysis

Snapshot

Sana Biotechnology is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 64/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~321% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

59
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

32
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Sana Biotechnology, Inc. (SANA) last printed $2.02. Equity value is $605.26M. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

20182019202020212022202320242025
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00

About

Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.

Sana Biotechnology (SANA) Stock Price & Analysis

SANA price $2.02 +0.01 +0.50%

Ticker
SANA
Price
$2.02
Change
+0.01 +0.50%
Market cap
$605.26M
Dividend yield
0.00%
Beta
2.30
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
64
Value
59
Quality
32
Growth
100

Stocklytics score rationale: value 59, quality 32, growth 100.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener